Cyclin G2: A novel independent prognostic marker in pancreatic cancer

Shinichiro Hasegawa, Hiroaki Nagano, Masamitsu Konno, Hidetoshi Eguchi, Akira Tomokuni, Yoshito Tomimaru, Hiroshi Wada, Naoki Hama, Koichi Kawamoto, Shogo Kobayashi, Shigeru Marubashi, Naohiro Nishida, Jun Koseki, Noriko Gotoh, Shouichi Ohno, Norikazu Yabuta, Hiroshi Nojima, Masaki Mori, Yuichiro Doki, Hideshi Ishii

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Unlike other cyclins that positively regulate the cell cycle, cyclin G2 (CCNG2) regulates cell proliferation as a tumor suppressor gene. A decreased CCNG2 expression serves as a marker for poor prognosis in several types of cancer. The aim of the present study was to clarify the correlation of CCNG2 expression with overall survival and histopathological factors in pancreatic cancer patients. This retrospective analysis included data from 36 consecutive patients who underwent complete surgical resection for pancreatic cancer and did not undergo any preoperative therapies. The association between prognoses and the expression of CCNG2 was assessed using immunohistochemical staining. Multivariate analysis identified that the expression of CCNG2 is an independent prognostic factor. In addition, the Kaplan-Meier curve for overall survival revealed that decreased expression of CCNG2 was a consistent indicator of poor prognosis in pancreatic cancer patients (P=0.0198). A decreased CCNG2 expression significantly correlated with venous invasion in tumor specimens and the tumor invasion depth. In conclusion, CCNG2 expression inversely reflected cancer progression and may be a novel, independent prognostic marker in pancreatic cancer.

Original languageEnglish
Pages (from-to)2986-2990
Number of pages5
JournalOncology Letters
Volume10
Issue number5
DOIs
Publication statusPublished - Nov 1 2015
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Cyclin G2: A novel independent prognostic marker in pancreatic cancer'. Together they form a unique fingerprint.

Cite this